Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis (Q37029012)
Jump to navigation
Jump to search
scientific article published on 05 May 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis |
scientific article published on 05 May 2013 |
Statements
1 reference
Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis (English)
1 reference
Hideki Mizunuma
1 reference
Toshitaka Nakamura
1 reference
Tetsuo Nakano
1 reference
Masako Ito
1 reference
Hiroshi Hagino
1 reference
Junko Hashimoto
1 reference
Masato Tobinai
1 reference
MOVER Study Group
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference